TY - JOUR
T1 - The carcinoGENOMICS project
T2 - critical selection of model compounds for the development of omics-based in vitro carcinogenicity screening assays
AU - Vinken, Mathieu
AU - Doktorova, Tatyana
AU - Ellinger-Ziegelbauer, Heidrun
AU - Ahr, Hans-Jürgen
AU - Lock, Edward A
AU - Carmichael, Paul
AU - Roggen, Erwin
AU - van Delft, Joost H
AU - Kleinjans, Jos
AU - Castell, José
AU - Bort, Roque
AU - Donato, Teresa
AU - Ryan, Michael P
AU - Corvi, Raffaella
AU - Keun, Hector C
AU - Ebbels, Timothy Mark David
AU - Athersuch, Toby J
AU - Sansone, Susanna-Assunta
AU - Rocca-Serra, Philippe
AU - Stierum, Rob
AU - Jennings, Paul
AU - Pfaller, Walter
AU - Gmuender, Hans
AU - Vanhaecke, Tamara
AU - Rogiers, Vera
PY - 2008/6/3
Y1 - 2008/6/3
N2 - Recent changes in the European legislation of chemical-related substances have forced the scientific community to speed up the search for alternative methods that could partly or fully replace animal experimentation. The Sixth Framework Program project carcinoGENOMICS was specifically raised to develop omics-based in vitro screens for testing the carcinogenic potential of chemical compounds in a pan-European context. This paper provides an in-depth analysis of the complexity of choosing suitable reference compounds used for creating and fine-tuning the in vitro carcinogenicity assays. First, a number of solid criteria for the selection of the model compounds are defined. Secondly, the strategy followed, including resources consulted, is described and the selected compounds are briefly illustrated. Finally, limitations and problems encountered during the selection procedure are discussed. Since selecting an appropriate set of chemicals is a frequent impediment in the early stages of similar research projects, the information provided in this paper might be extremely valuable.
AB - Recent changes in the European legislation of chemical-related substances have forced the scientific community to speed up the search for alternative methods that could partly or fully replace animal experimentation. The Sixth Framework Program project carcinoGENOMICS was specifically raised to develop omics-based in vitro screens for testing the carcinogenic potential of chemical compounds in a pan-European context. This paper provides an in-depth analysis of the complexity of choosing suitable reference compounds used for creating and fine-tuning the in vitro carcinogenicity assays. First, a number of solid criteria for the selection of the model compounds are defined. Secondly, the strategy followed, including resources consulted, is described and the selected compounds are briefly illustrated. Finally, limitations and problems encountered during the selection procedure are discussed. Since selecting an appropriate set of chemicals is a frequent impediment in the early stages of similar research projects, the information provided in this paper might be extremely valuable.
KW - Animal Testing Alternatives
KW - Carcinogenicity Tests
KW - European Union
KW - Gene Expression Profiling
KW - Genomics
KW - Hazardous Substances
KW - International Cooperation
KW - Toxicogenetics
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
KW - Review
U2 - 10.1016/j.mrrev.2008.04.006
DO - 10.1016/j.mrrev.2008.04.006
M3 - Review article
C2 - 18514569
SN - 1383-5742
VL - 659
SP - 202
EP - 210
JO - Mutation Research/Reviews in Mutation Research
JF - Mutation Research/Reviews in Mutation Research
IS - 3
ER -